Incyte Corporation
COMBINATION THERAPY COMPRISING AXL/MER AND PD-1/PD-L1 INHIBITORS

Last updated:

Abstract:

The present disclosure relates to methods of treating cancer by administering a compound, which is an AXL/MER kinase inhibitor, in combination with an antibody, or an antibody fragment thereof, that binds to PD-1.

Status:
Application
Type:

Utility

Filling date:

5 Mar 2021

Issue date:

9 Sep 2021